Trials / Completed
CompletedNCT01674595
An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is an open, national, multi-centre trial. The trial will be initiated after olive pollen season 2012 and subjects will receive treatment for 6 weeks. The aim of study is to assess the tolerability of the up-dosing phase of AVANZ Olive. The frequency of patients with adverse reactions will be the primary endpoint. Frequency of patients with systemic reactions according to EAACI classification, increase in IgG4 and in IgE and reduction in immediate skin reactivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AVANZ olea | Immunotherapy Olea europaea |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2012-08-29
- Last updated
- 2013-04-30
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT01674595. Inclusion in this directory is not an endorsement.